Cooperative Agreement UG3EY036558
Award Date 9/15/25
Completion Date 5/31/30
Dollars Obligated $23K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Virginia, USA
Similar Awards
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $330,169 to ESK Therapeutics, Inc. to commercialize a biologic eyedrop formulation called CornealClear for the treatment of persistent corneal epithelial defects (PCED). The project aims to demonstrate that the CornealClear eyedrops can accelerate corneal wound healing and reduce scarring in a rabbit model, as well as confirm the systemic safety of the prolactin-induced protein (PIP) formulation. If...
- This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to advance the development of the drug filociclovir (FCV) for the treatment of adenoviral conjunctivitis and epidemic keratoconjunctivitis. The $674,963 award to Microbiotix, Inc. will fund the completion of key preclinical activities, including finalizing the eye drop formulation, conducting IND-enabling toxicology studies in rabbits and rats, and completing regulatory...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support (CFDA 93.310) program provides $498,248 to the University of Connecticut Health Center (UCHC) to investigate the molecular mechanisms underlying corneal and retinal injury caused by exposure to chemical threat agents like nitrogen mustard. The key objectives are to: 1) Examine the role of the p53-PAD axis in driving corneal hypercitrullination, a pathological response, after nitrogen...
- This Project Grant award from the Department of Health and Human Services' National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $1,467,198.00 to the University of Connecticut Health Center (UCHC) to investigate the cellular and molecular mechanisms of corneal and sensory nerve damage caused by exposure to chemical warfare agents. The key products and services to be delivered under this 3-year award, which runs from September 15, 2025 to August...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $295,500.00 to The Schepens Eye Research Institute, Inc. to develop a neuropeptide-based countermeasure to mitigate ocular damage from exposure to mustard gas agents. The research aims to assess the therapeutic efficacy of topical alpha-melanocyte-stimulating hormone (α-MSH) treatment in preventing corneal damage, nerve loss, and inflammation in a mouse model of...
- This $332,179 Project Grant awarded by the National Eye Institute (CFDA 93.867 Vision Research) supports the development of nanobarrier contact lenses that can provide sustained delivery of the drug cysteamine to treat the ocular complications of cystinosis. The lenses are designed to replace the current 8-times daily eye drop regimen, improving patient compliance and reducing side effects from the preservatives and acidic pH in the eye drops. The project aims to demonstrate the lenses can...
- This Project Grant award of $394,285, funded by the National Eye Institute (CFDA 93.867 - Vision Research), supports research at the University of Houston to develop decorin-based drugs for treating corneal scarring and neovascularization. The key objectives are to characterize the binding interfaces of decorin with TGF-β1 and VEGFR2 in order to engineer novel decorin mimetic drugs. This research aims to provide alternative treatment options for preventing corneal opacity and vision loss...
- This $305,321 Project Grant awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports the clinical development and commercialization of a topical ophthalmic treatment for neovascular age-related macular degeneration (NAMD). The funding will enable the awardee, Neovascularx, Inc., to advance their AMD101 (rifampicin) compound, which aims to provide a less invasive, home-based alternative to the current standard of care intravitreous injections for...
- The National Eye Institute (NEI) awarded a $482,067 Project Grant to Washington State University (WSU) on August 1, 2025 under the Vision Research federal grant program (CFDA 93.867). The grant supports research to develop novel nanotherapies for the targeted treatment of corneal neovascularization, a sight-threatening condition characterized by the growth of blood vessels into the cornea. The funding will enable WSU researchers to synthesize a unique trehalose-based dendrimer (TRE-D) that...
- This Project Grant award of $212,936.00 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research by the University of Louisville to optimize C-MET signaling to enhance corneal epithelial homeostasis. The research aims to determine if inhibiting the ubiquitylation and downregulation of the C-MET receptor can prolong its signaling and accelerate corneal wound healing. This is particularly relevant as corneal blindness is the 4th leading cause of blindness globally, often...